M&A Radar — Cross-Cohort Signal-Arc Detection

Generated: 2026-04-27 16:11 UTC Universe: 75 deep-researched entities Method: 5-indicator Iodine pre-acquisition signal-arc model, run against recent_news + press_releases corpus Output: /tmp/combined_audit.json (full-detail) + this memo

Methodology

The Waystar/Iodine 2025 transaction had 5 retrospectively-observable leading indicators in our pipeline. We codify them as a 0-5 score and run against the full registry.

Headline finding

Only 2 of 75 entities currently flag the CEO-succession indicator: MarketWise and Prime Healthcare. Surprisingly, Nym Health does not — the Lori Jones transition lives in LinkedIn data, not in our text corpus yet. Indicator 1 has a known false-negative rate that needs the LinkedIn delta layer to close.

Top 20 by M&A radar score

Indicator flags shown as [CEO][Founder][Press][CorpDev][Quiet] — Y = match, . = no match.

Strategic reads

Tier 1 — Most-Acquirable-Now (CEO + Press combo)

MarketWise (Y.Y..) and Prime Healthcare (Y.Y..) are the only two entities matching both the CEO-succession AND press-acceleration patterns. These are the closest matches to the Iodine pre-deal signature in our registry today.

• MarketWise: Public company (NASDAQ: MKTW). Recent corporate-governance announcements + special-committee filings (SEC visible). The combination of governance volatility + press cadence + the Iodine-precedent in adjacent newsletter sector is a buy-side trigger. Likely take-private candidate.
• Prime Healthcare: 51-hospital health system. CEO transition + sustained press output is unusual at this scale; likely tied to a strategic transaction or governance change.

Tier 2 — Press + Quiet-Period combo (10 entities)

Pattern: high cumulative press cadence but cooling in the trailing 30 days. Either (a) approaching M&A quiet period, (b) reorganization mode, or (c) artifact of sparse date metadata. Most strategically interesting entries in this tier:

• Codametrix — already flagged in the medical-coding memo as the strongest standalone trajectory; the quiet-period flag could indicate an imminent product launch OR an in-progress strategic round.
• Iodine Software — score 2 even post-acquisition. Validates that the heuristic catches actual M&A patterns retrospectively.
• Fathom Health — explicit medical-coding-AI peer; M&A-ready signature now visible.
• Komodo Health — healthcare-data adjacency to the Optum portfolio.
• Heartland Ventures — VC entity; quiet-period for a fund usually = fund-raising or wind-down.

Tier 3 — Press-only (54 entities, score=1)

Press acceleration without CEO/quiet-period co-signals. The base rate of press activity is too high to be a useful M&A indicator on its own. Filter heuristic for next iteration: require >=8 press AND >=2 SEC filings in trailing window to count as Tier-3 candidate.

Tier 4 — No indicators (7 entities)

Remaining 7 entities have no signal-arc match. Likely either (a) recently added with limited deep-research history, or (b) genuinely not in M&A mode. Worth re-running after the next continuous-research cycle.

Pipeline self-critique

This first-iteration heuristic has known limitations:

1. Indicator 1 (CEO succession) is text-only — misses LinkedIn-only signals like Lori Jones at Nym. Fix: integrate org_chart_deep delta detection (compare current run vs prior).
2. Indicator 2 (Founder departure) caught zero entities — too restrictive regex. Fix: add LinkedIn role_history.end_year > prior_run.role_history.end_year delta.
3. Indicator 4 (Corp-dev) caught zero entities — corp-dev hires don't appear in target-entity press; they appear in acquirer press. Fix: invert the lookup — for each candidate target, scan declared-acquirer-set's recent news for corp-dev hires.
4. Press-cadence threshold (>=6) too low — 68 of 75 hit it, providing no discrimination. Fix: require trailing-30d acceleration (press_30d >= 4) as a cleaner signal.

Recommended actions

1. Deploy LinkedIn-delta detection as Wave 7 of the deep-research pipeline. Compare per-entity org_chart_deep vs prior run; flag CEO/Founder role changes.
2. Add Waystar's news/press feed as a "predator" reference — when Waystar's news mentions corp-dev hires, that's a leading indicator for ALL Tier-2 medical-coding cohort entities.
3. Re-run M&A radar nightly as part of the continuous wrapper — cheap (~30 lines) and the indicator data is already collected per cycle.
4. Manual review pass on MarketWise + Prime Healthcare — verify the CEO-succession matches are real signals not parsing artifacts. If real, both are immediate corp-dev targets. Co-Authored-By: Oz oz-agent@warp.dev